A snapshot of NIAID-supported research to improve screening, prevention and treatment for hepatitis B and C.

Friday, July 28, 2023 Hepatitis B and C—A Closer Look at NIAID Research to Accelerate Elimination NIAID supports research to improve screening, prevention and treatment for hepatitis B and C, which account for the majority of viral hepatitis disease burden worldwide. The NIAID Now blog features a snapshot of current hepatitis B and C research, part of the latest efforts in NIAID's 60-year pursuit of scientific advances to improve the health outcomes of people with viral hepatitis. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107